CN105637367A - 胰腺癌相关材料和方法 - Google Patents

胰腺癌相关材料和方法 Download PDF

Info

Publication number
CN105637367A
CN105637367A CN201480056359.9A CN201480056359A CN105637367A CN 105637367 A CN105637367 A CN 105637367A CN 201480056359 A CN201480056359 A CN 201480056359A CN 105637367 A CN105637367 A CN 105637367A
Authority
CN
China
Prior art keywords
tumor
protein
pancreatic
proteins
phosphorylation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480056359.9A
Other languages
English (en)
Chinese (zh)
Inventor
Z·尤
N·希顿
A·夸利亚
D·布里顿
M·沃德
I·派克
V·米特拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proteome Sciences PLC
Kings College Hospital NHS Foundation Trust
Original Assignee
Electrophoretics Ltd
Kings College Hospital NHS Foundation Trust
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Electrophoretics Ltd, Kings College Hospital NHS Foundation Trust filed Critical Electrophoretics Ltd
Publication of CN105637367A publication Critical patent/CN105637367A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Peptides Or Proteins (AREA)
  • Gastroenterology & Hepatology (AREA)
CN201480056359.9A 2013-08-13 2014-08-13 胰腺癌相关材料和方法 Pending CN105637367A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1314485.2 2013-08-13
GBGB1314485.2A GB201314485D0 (en) 2013-08-13 2013-08-13 Materials and methods relating to pancreatic cancer
PCT/GB2014/052475 WO2015022530A2 (en) 2013-08-13 2014-08-13 Materials and methods relating to pancreatic cancer

Publications (1)

Publication Number Publication Date
CN105637367A true CN105637367A (zh) 2016-06-01

Family

ID=49262110

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480056359.9A Pending CN105637367A (zh) 2013-08-13 2014-08-13 胰腺癌相关材料和方法

Country Status (7)

Country Link
US (1) US20160195536A1 (https=)
EP (1) EP3033624A2 (https=)
JP (1) JP2016535270A (https=)
CN (1) CN105637367A (https=)
CA (1) CA2920946A1 (https=)
GB (1) GB201314485D0 (https=)
WO (1) WO2015022530A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107923918A (zh) * 2015-09-09 2018-04-17 私募蛋白质体公司 用于开发个性化药物治疗计划和基于蛋白质组谱的靶向药物开发的方法
CN112585470A (zh) * 2018-06-21 2021-03-30 乌得勒支大学控股有限责任公司 用于监测样品中激酶活性的方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10617720B2 (en) * 2016-10-20 2020-04-14 Miltenyi Biotech, GmbH Chimeric antigen receptor specific for tumor cells
JP2020514684A (ja) * 2016-12-20 2020-05-21 トリート４ライフ アーベー 質量分析によってｂｒａｆ突然変異および野生型ｂｒａｆタンパク質を定める方法
CN111066727B (zh) * 2019-12-20 2021-08-27 中国人民解放军陆军军医大学 在低氧性血睾屏障通透中作用机制的小鼠模型构建方法
IT202000016807A1 (it) * 2020-07-10 2022-01-10 Humanitas Mirasole Spa Peptidi associati a tumore e loro impiego
JPWO2022154037A1 (https=) * 2021-01-14 2022-07-21

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1726395A (zh) * 2002-12-17 2006-01-25 北京诺赛基因组研究中心有限公司 胰腺癌的特异标记

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
WO2003016861A2 (en) 2001-08-14 2003-02-27 President And Fellows Of Harvard College Absolute quantification of proteins and modified forms thereof by multistage mass spectrometry
WO2004055519A2 (en) * 2002-12-17 2004-07-01 Sinogenomax Co. Ltd. Specific markers for pancreatic cancer
US8346482B2 (en) * 2003-08-22 2013-01-01 Fernandez Dennis S Integrated biosensor and simulation system for diagnosis and therapy
DE102006056784A1 (de) * 2006-12-01 2008-06-05 Meyer, Helmut E., Prof.Dr. Biomarker für die Diagnose von Pankreaskrebs
GB0704764D0 (en) 2007-03-12 2007-04-18 Electrophoretics Ltd Isobarically labelled reagents and methods of their use
WO2009146545A1 (en) * 2008-06-05 2009-12-10 University Health Network Compositions and methods for classifying lung cancer and prognosing lung cancer survival
EP2391891A1 (en) * 2009-01-27 2011-12-07 Proteogenix, Inc. Biomarkers for detection of neonatal sepsis in biological fluid
US20130023436A1 (en) * 2010-01-15 2013-01-24 Bryan William Jones Disease diagnosis and treatment using computational molecular phenotyping
WO2011092338A1 (en) * 2010-02-01 2011-08-04 Ab Science Combined treatment of pancreatic cancer with gemcitabine and masitinib
CN102947706B (zh) * 2010-04-19 2018-04-13 生物标志物策略公司 预测药物敏感性、抗性和疾病进展的组合物和方法
AU2011260390B2 (en) * 2010-06-01 2016-11-24 Ernst-Moritz-Arndt Universitat Greifswald Means and methods for diagnosing pancreatic cancer in a subject
EP2582727B8 (en) * 2010-06-16 2017-04-19 University of Pittsburgh- Of the Commonwealth System of Higher Education Antibodies to endoplasmin and their use
US20140222443A1 (en) * 2011-06-07 2014-08-07 Kathleen Danenberg Molecular profiling for cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1726395A (zh) * 2002-12-17 2006-01-25 北京诺赛基因组研究中心有限公司 胰腺癌的特异标记

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAVID BRITTON ET AL.: "Quantification of Pancreatic Cancer Proteome and Phosphorylome: Indicates Molecular Events Likely Contributing to Cancer and Activity of Drug Targets", 《PLOS ONE》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107923918A (zh) * 2015-09-09 2018-04-17 私募蛋白质体公司 用于开发个性化药物治疗计划和基于蛋白质组谱的靶向药物开发的方法
CN112585470A (zh) * 2018-06-21 2021-03-30 乌得勒支大学控股有限责任公司 用于监测样品中激酶活性的方法

Also Published As

Publication number Publication date
EP3033624A2 (en) 2016-06-22
JP2016535270A (ja) 2016-11-10
CA2920946A1 (en) 2015-02-19
WO2015022530A3 (en) 2015-04-09
WO2015022530A2 (en) 2015-02-19
US20160195536A1 (en) 2016-07-07
GB201314485D0 (en) 2013-09-25

Similar Documents

Publication Publication Date Title
Lucarelli et al. Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml
Old et al. Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma
Schrödter et al. Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinoma
Mikula et al. Integrating proteomic and transcriptomic high-throughput surveys for search of new biomarkers of colon tumors
CN105637367A (zh) 胰腺癌相关材料和方法
Britton et al. Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets
Maes et al. Proteomics in cancer research: Are we ready for clinical practice?
Ghosh et al. A cell-surface membrane protein signature for glioblastoma
Hadisurya et al. Quantitative proteomics and phosphoproteomics of urinary extracellular vesicles define putative diagnostic biosignatures for Parkinson’s disease
Gajbhiye et al. Urinary proteome alterations in HER2 enriched breast cancer revealed by multipronged quantitative proteomics
Saraswat et al. Comparative proteomic profiling of the serum differentiates pancreatic cancer from chronic pancreatitis
US20240084394A1 (en) Urinary metabolomic biomarkers for detecting colorectal cancer and polyps
Vellaichamy et al. Proteomic interrogation of androgen action in prostate cancer cells reveals roles of aminoacyl tRNA synthetases
HK1248316A1 (en) Methods of assessing colorectal health of an individual
Jiang et al. iTRAQ‐based quantitative proteomics approach identifies novel diagnostic biomarkers that were essential for glutamine metabolism and redox homeostasis for gastric cancer
GB2551415A (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
Duangkumpha et al. Discovery and qualification of serum protein biomarker candidates for cholangiocarcinoma diagnosis
Pavlou et al. Coupling proteomics and transcriptomics in the quest of subtype‐specific proteins in breast cancer
Wu et al. Next-generation novel noninvasive cancer molecular diagnostics platforms beyond tissues
US20260092922A1 (en) Markers for the diagnosis of biochemical recurrence in prostate cancer
CN110121647A (zh) 用于检测和治疗胰腺导管腺癌的方法
Chinello et al. The proteomic landscape of renal tumors
Sun et al. From clinic to mechanism: Proteomics‐based assessment of angiogenesis in adrenal pheochromocytoma
Chen et al. Integrated tissue proteome and metabolome reveal key elements and regulatory pathways in cutaneous squamous cell carcinoma
Liu et al. Dysregulation of phosphoproteins in hepatocellular carcinoma revealed via quantitative analysis of the phosphoproteome

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: London, England

Applicant after: Electrophoretics Limited

Applicant after: KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST

Address before: surrey

Applicant before: Electrophoretics Limited

Applicant before: KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST

CB02 Change of applicant information
RJ01 Rejection of invention patent application after publication

Application publication date: 20160601

RJ01 Rejection of invention patent application after publication